A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Phesgo® Biosimilar HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Qi Jin
- Telefonnummer: 86 159 5516 0489
- E-Mail: Qi_jin@henlius.com
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Voluntary participation in the clinical study and signed the Informed Consent Form (ICF).
- Male or female aged ≥ 18 years old at the time of signing the ICF;
- Histologically confirmed invasive breast cancer, stage II-IIIC, Human Epidermal Growth Factor Receptor 2 (HER2) positive confirmed by central laboratory.
- Participants agree to undergo surgery while meeting the criteria for surgery after neoadjuvant therapy.
- Left ventricular ejection fraction (LVEF) at baseline ≥ 55%.
- An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1.
- Adequate major organ functions.
- Women with child-bearing potential have a negative result of serum pregnancy test at screening period (within 7 days prior to the first dose) or if they are infertile, non- lactating, reproduction-age men and women following highly effective contraceptive measures until 7 months after last dose.
Exclusion Criteria:
- Stage IV breast cancer, bilateral breast cancer, or multicentric breast cancer.
- History of other malignancy within 5 years.
- Prior systemic therapy for breast cancer treatment or radiotherapy.
- Patients with a history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) who have received systemic therapy or radiotherapy to the ipsilateral breast.
- Patients who have undergone excision biopsy of the primary tumor and/or axillary lymph nodes or lymph node dissection.
- Have severe heart disease or medical conditions.
- Participants with viral hepatitis or those with autoimmune hepatitis, sclerosing cholangitis, or liver cirrhosis.
- Human Immunodeficiency Virus (HIV) infection, HIV antibody positive.
- Daily use of corticosteroid treatment is required.
- Sensitivity to any study medications or any of its ingredients or excipients.
- Participants who underwent any major surgery within 28 days prior to the first dose. Or participants who have received local radiotherapy, radiofrequency ablation, or interventional therapy within 2 weeks prior to the first dose.
- Received another interventional clinical trial therapy within 4 weeks prior to enrollment in the study, or intentionally participated in another interventional clinical trial during the entire study period.
- Severe, uncontrolled systemic diseases that may currently interfere with the therapeutic plan.
- Any other conditions which are inappropriate for the study in the opinion of the investigator.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: HLX319
The regimen in the experimental group is HLX319 in combination with docetaxel and carboplatin.
|
HLX319 is a biosimilar of pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)
|
|
Aktiver Komparator: EU-Phesgo®
The regimen in the control group is EU-Phesgo® in combination with docetaxel and carboplatin.
|
EU-Phesgo® is an original marketed drug product, with the generic name pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Peak concentration (Cmax)
Zeitfenster: up to 180 days
|
Peak concentration after a single drug administration in Cycle 1.
|
up to 180 days
|
|
Area under the serum drug concentration-time curve from 0 to 21 days (AUC0-21d)
Zeitfenster: up to 180 days
|
Area under the serum drug concentration-time curve from 0 to 21 days after a single drug administration in Cycle 1.
|
up to 180 days
|
|
Steady-state peak concentration (Cmax,ss)
Zeitfenster: up to 180 days
|
The steady-state peak concentration after multiple doses administration in Cycle 4.
|
up to 180 days
|
|
Steady-state area under the serum drug concentration-time curve within a dosing interval (AUCss)
Zeitfenster: up to 180 days
|
Steady-state area under the serum drug concentration-time curve within a dosing interval after multiple doses administration in Cycle 4.
|
up to 180 days
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Trough concentration (Ctrough)
Zeitfenster: up to 180 days
|
Trough concentration after a single dose administration
|
up to 180 days
|
|
Area under the serum drug concentration-time curve from time 0 to infinity (AUC0-inf)
Zeitfenster: up to 180 days
|
Area under the serum drug concentration-time curve from time 0 to infinity after a single dose administration
|
up to 180 days
|
|
Percentage of extrapolated area in the total AUC (%AUCex)
Zeitfenster: up to 180 days
|
Percentage of extrapolated area in the total AUC after a single dose administration
|
up to 180 days
|
|
Time to peak concentration (Tmax)
Zeitfenster: up to 180 days
|
time to peak concentration after a single dose administration
|
up to 180 days
|
|
Elimination half-life (T1/2)
Zeitfenster: up to 180 days
|
elimination half-life after a single dose administration
|
up to 180 days
|
|
Total clearance (CL/F)
Zeitfenster: up to 180 days
|
total clearance after a single dose administration
|
up to 180 days
|
|
Terminal phase distribution volume (Vz/F)
Zeitfenster: up to 180 days
|
terminal phase distribution volume after a single dose administration
|
up to 180 days
|
|
Mean residence time (MRT)
Zeitfenster: up to 180 days
|
mean residence time after a single dose administration
|
up to 180 days
|
|
Steady-state trough concentration (Ctrough,ss)
Zeitfenster: up to 180 days
|
steady-state trough concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Average steady-state concentration (Caverage,ss)
Zeitfenster: up to 180 days
|
average steady-state concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state time to peak concentration (Tmax,ss)
Zeitfenster: up to 180 days
|
steady-state time to peak concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Elimination half-life (T1/2,ss)
Zeitfenster: up to 180 days
|
elimination half-life after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state volume of distribution (Vss/F)
Zeitfenster: up to 180 days
|
steady-state volume of distribution after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state total clearance (CLss/F)
Zeitfenster: up to 180 days
|
steady-state total clearance after multiple doses administration in Cycle 4
|
up to 180 days
|
|
accumulation ratio based on Cmax (RCmax)
Zeitfenster: up to 180 days
|
accumulation ratio based on Cmax after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Accumulation ratio based on AUC (RAUC)
Zeitfenster: up to 180 days
|
accumulation ratio based on AUC after multiple doses administration in Cycle 4
|
up to 180 days
|
|
The total pathological complete response (tpCR) rate assessed by the investigator
Zeitfenster: up to 180 days
|
up to 180 days
|
|
|
Breast pathologic complete response (bpCR) rate assessed by the investigator
Zeitfenster: up to 180 days
|
up to 180 days
|
|
|
Objective response rate (ORR) assessed by the investigator
Zeitfenster: up to 180 days
|
according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria
|
up to 180 days
|
|
Incidence and severity of adverse events (AEs)
Zeitfenster: up to 180 days
|
severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 6.0
|
up to 180 days
|
|
Number of participants with abnormal vital signs
Zeitfenster: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal physical examination findings
Zeitfenster: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal Laboratory tests results
Zeitfenster: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal 12-lead ECG readings
Zeitfenster: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Positivity rates of anti-drug antibodies (ADA)
Zeitfenster: up to 180 days
|
up to 180 days
|
|
|
Positivity rates of neutralizing antibodies (NAb)
Zeitfenster: up to 180 days
|
up to 180 days
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- HLX319-BC001
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .